Real-world cure rates for hepatitis C virus treatments that include simeprevir and/or sofosbuvir are comparable to clinical trial results

doi:10.5501/wjv.v6.i4.59

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 6, Issue 4

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Supplementary Materials of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (11286)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-2) series, Tables (1-8) series.

Item

Count

PDF

620

WORD

361

HTML

4366

Figures (1-2)

189

Tables (1-8)

210

Sum=5746

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

1199

Download

1395

Sum=2594

Publishing Process of This Article

Item

Count

Browse

1140

Download

1806

Sum=2946

Nov 12, 2017 (publication date) through Apr 25, 2024

Times Cited of This Article

Times Cited (4)

Journal Information of This Article

Publication Name

World Journal of Virology

ISSN

2220-3249

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Observational Study

World J Virol. Nov 12, 2017; 6(4): 59-72
Published online Nov 12, 2017. doi: 10.5501/wjv.v6.i4.59

Full Size Figure Download Figure

Figure 2 Forest plot of sustained virological response 12 rates for 470 patients with confirmed outcomes. A: SMV/SOF ± RBV; B: SOF/RBV; C: SOF/PEG/RBV. Dotted lines represent the separation of categories. The sustained virological response 12 rate, number in each subgroup, and P value of the categorical comparison are shown below the graph. SMV: Simeprevir; SOF: Sofosbuvir; RBV: Ribavirin; PEG: pegylated-interferon.

Citation: Bichoupan K, Tandon N, Crismale JF, Hartman J, Del Bello D, Patel N, Chekuri S, Harty A, Ng M, Sigel KM, Bansal MB, Grewal P, Chang CY, Leong J, Im GY, Liu LU, Odin JA, Bach N, Friedman SL, Schiano TD, Perumalswami PV, Dieterich DT, Branch AD. Real-world cure rates for hepatitis C virus treatments that include simeprevir and/or sofosbuvir are comparable to clinical trial results. World J Virol 2017; 6(4): 59-72
URL: https://www.wjgnet.com/2220-3249/full/v6/i4/59.htm
DOI: https://dx.doi.org/10.5501/wjv.v6.i4.59